Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSONASDAQ:HYPRNASDAQ:NRXSNASDAQ:SURG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$1.18-2.1%$0.99$0.70▼$1.61$74.26M1.05148,271 shs34,878 shsHYPRHyperfine$0.71-1.5%$0.70$0.53▼$1.90$55.03M0.95898,192 shs156,187 shsNRXSNeurAxis$2.52+3.3%$2.45$1.33▼$6.20$18.18M3.34860,260 shs27,108 shsSURGSurgePays$3.00+1.9%$2.84$1.05▼$3.47$61.54M0.43630,580 shs121,876 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-4.76%0.00%+42.01%+17.65%+55.68%HYPRHyperfine+4.25%+3.27%+32.75%-9.35%-13.26%NRXSNeurAxis+2.95%-3.56%-19.47%+14.02%-4.69%SURGSurgePays+7.69%+9.29%-3.92%+25.11%-11.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents1.7626 of 5 stars3.52.00.00.01.80.00.6HYPRHyperfine2.2954 of 5 stars3.33.00.00.00.62.50.6NRXSNeurAxis2.1565 of 5 stars3.53.00.00.00.03.30.0SURGSurgePays2.9801 of 5 stars3.55.00.00.01.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$5.50368.09% UpsideHYPRHyperfine 2.67Moderate Buy$1.0648.88% UpsideNRXSNeurAxis 3.00Buy$7.00177.78% UpsideSURGSurgePays 3.00Buy$9.00200.50% UpsideCurrent Analyst Ratings BreakdownLatest NRXS, CTSO, HYPR, and SURG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.006/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.006/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.685/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/22/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.50 ➝ $8.75(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.60M2.07N/AN/A$0.20 per share5.88HYPRHyperfine$11.73M4.72N/AN/A$0.67 per share1.06NRXSNeurAxis$2.93M6.20N/AN/A($0.27) per share-9.33SURGSurgePays$40.03M1.53N/AN/A$0.76 per share3.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)HYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/6/2025 (Estimated)NRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/ASURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)Latest NRXS, CTSO, HYPR, and SURG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/25/2025Q4 2024SURGSurgePays-$0.27-$0.93-$0.66-$1.02$8.22 million$9.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents0.982.612.30HYPRHyperfineN/A6.075.48NRXSNeurAxisN/A0.240.23SURGSurgePays0.241.721.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%HYPRHyperfine15.03%NRXSNeurAxis11.77%SURGSurgePays6.94%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents6.60%HYPRHyperfine30.98%NRXSNeurAxis26.40%SURGSurgePays30.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.61 million58.48 millionOptionableHYPRHyperfine19077.83 million53.72 millionOptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableSURGSurgePays4020.41 million14.19 millionOptionableNRXS, CTSO, HYPR, and SURG HeadlinesRecent News About These CompaniesSurgePays (NASDAQ:SURG) Share Price Crosses Above Two Hundred Day Moving Average - Here's WhyJune 24 at 4:14 AM | marketbeat.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.00 at Ascendiant Capital MarketsJune 18, 2025 | americanbankingnews.comSurgePays (NASDAQ:SURG) Price Target Raised to $9.00June 16, 2025 | marketbeat.comSurgePays to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25June 11, 2025 | prnewswire.comSurgePays, Inc. (NASDAQ:SURG) Sees Significant Decrease in Short InterestJune 4, 2025 | marketbeat.comSurgePays (NASDAQ:SURG) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?May 31, 2025 | marketbeat.comSurgePays Confirms Directors and Ratifies Accounting FirmMay 20, 2025 | tipranks.comAT&T (NYSE:T) Partners With Carbyne For APEX Continuity Emergency Solution For PSAPsMay 20, 2025 | finance.yahoo.comUS$8.75 - That's What Analysts Think SurgePays, Inc. (NASDAQ:SURG) Is Worth After These ResultsMay 17, 2025 | uk.finance.yahoo.comSurgePays Secures $7M Convertible Note for ExpansionMay 16, 2025 | tipranks.comWhy SurgePays, Inc.’s (SURG) Stock Is Down 19.64%May 15, 2025 | aaii.comQ1 2025 Surgepays Inc Earnings CallMay 15, 2025 | uk.finance.yahoo.comSurgePays, Inc. (SURG) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comSurgePays, Inc. (SURG) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comSurgePays Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comSurgePays Announces $7 Million Debt Financing to Accelerate GrowthMay 13, 2025 | prnewswire.comSurgePays to Host First Quarter 2025 Financial Results Conference Call on Tuesday, May 13thMay 6, 2025 | prnewswire.comEarnings Preview: SurgePays, Inc. (SURG) Q1 Earnings Expected to DeclineMay 5, 2025 | zacks.comPOS Fintech SurgePays Launches on AT&TApril 28, 2025 | crowdfundinsider.comSurgePays Launches Nationwide on AT&T Network with 250,000 SIMs ShippedApril 24, 2025 | prnewswire.comSurgePays Promotes Derron Winfrey to President, Sales and OperationsApril 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceNRXS, CTSO, HYPR, and SURG Company DescriptionsCytosorbents NASDAQ:CTSO$1.18 -0.03 (-2.08%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Hyperfine NASDAQ:HYPR$0.71 -0.01 (-1.55%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.NeurAxis NASDAQ:NRXS$2.52 +0.08 (+3.28%) As of 12:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.SurgePays NASDAQ:SURG$3.00 +0.06 (+1.87%) As of 12:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
